Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
At ASCO GI, Leap Therapeutics announced that in a trial of DKN-01 in patients with advanced gastric cancer, elevated expression of DKK1 is correlated with high responses to the drug.
Read Source